Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1653-1660

  Gupta, Malini ^a   Fan, Saijun ^a   Zhan, Qimin ^a   Kohn, Kurt W ^a   O'Connor, Patrick M ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL CYCLE G1 PHASE; CLONOGENESIS; COLON CARCINOMA; DNA DAMAGE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OLIGONUCLEOTIDE PROBE; PAPILLOMA VIRUS; PRIORITY JOURNAL; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA DAMAGE; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; ENZYME INHIBITORS; ESTROGENS; FEMALE; FLOW CYTOMETRY; G1 PHASE; GENES, P53; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NOCODAZOLE; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TOPOISOMERASE I INHIBITORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030879102     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
2. Livingstone, I. R., White, A., Sprouse, J., Livanos, E., Jack, T., and Tilsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
3. Lane, D. P. p53 guardian of genome. Nature (Lond.), 358: 15-16, 1992.
4. Selivanova, G., and Wiman, K. G. p53. A cell cycle regulator activated by DNA damage. Adv. Cancer Res., 66: 143-180, 1995.
5. Smith, M. L., and Fornace, A. J., Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol., 7: 69-75, 1995.
6. Smith, M. L., Chen, T. I., Zhan, Q., O'Connor, P. M., and Fornace, A. J. Involvement of the p53 tumor suppressor in repair of U. V.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
7. Fan, S., Smith, M. L., Rivet II, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
8. 2-M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
9. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line., Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
10. Powell, S. N., De Frank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., Tang, W., and Friend, S. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and over-ride of G2 delay. Cancer Res., 55: 1643-1648, 1995.
11. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
12. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
13. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
14. 1 checkpoint does not decrease cell survival following DNA damage., Cancer Res., 53: 4164-4168, 1993.
15. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the NCI anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res., in press, 1997.
16. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 7262: 1-14, 1995.
17. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins, Semin. Oncol., 23: 1-10, 1996.
18. Shimada, Y., Rothenberg, M., Hilsenbeck, S. G., Burris, H. A., Degen, D., and Von Hoff, D. D. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human colony-forming units. Anticancer Drugs, 5: 202-206, 1994.
19. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer. Chemother. Pharmacol., 21: 71-74, 1988.
20. Hoki, Y., Fujimori, A., and Pommier, Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol., in press, 1997.
21. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donchower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
22. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
23. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
24. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/ C2, a human leukemia cell lines resistant to camptothecin. Cancer Res., 55: 1339-1346, 1995.
25. Kohn, K. W., Ewig, R. A., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
26. Bertrand, R., and Pommier, Y. Assessment of DNA damage in mammalian cells by DNA filter elution methodology. In: G. P. Studzinski (ed.), Cell Growth and Apoptosis, pp. 97-117. Newark: Oxford University Press, 1995.
27. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in Mammalian cells by campto-thecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989.
28. Bertrand, R., Kohn, K. W., Solary, E., and Pommier, Y. Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. Drug Dev. Res., 34: 138-144, 1995.
29. Zhan, Q., Carrier, F., and Fornace, A. J. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol., 13: 4242-4250, 1993.
30. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., and O'Connor, P. M. Cells lacking CIP/WAF1 genes exhibit enhanced sensitivity to cisplatin and nitrogen mustard., Oncogene, 14: 2127-2136, 1997.
31. Logan, T., Evans, D., Mercer, W., Bjornsti, M., and Hall, D. Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins., Cancer Res., 55: 2883-2891, 1995.
32. Xu, C., Meikrantz, W., Schlegel, R., and Sager, R. The human papilloma virus 16 E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc. Natl. Acad. Sci. USA, 92: 7829-7833, 1995.
33. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
34. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
35. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
36. Smith, M. L., Chen, I-T., Zhan, Q., Bae, I., Chen, C-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M., and Fornace, A. J. Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376-1380, 1994.
37. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
38. Tishler, R. B., Calderwood, S. K., Coleman, C. N., and Price, B. D. Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53: 2212-2216, 1993.
39. 1 arrest. Proc. Natl. Acad. Sci. USA, 93: 4827-4832, 1996.
40. Reed, M., Woelker, B., Wang, P., Wang, Y., Anderson, M. E., and Tegtmeyer, P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA, 92: 9455-9459, 1995.
41. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
42. Ishizaka, Y., Chernov, V. M., Burns, C. M., and Stark, G. R. p53-dependent growth arrest of REF52 cells containing newly amplified DNA. Proc. Natl. Acad. Sci. USA, 92: 3224-3228, 1995.
43. Hickey, R. J., and Malkas, L. H. Mammalian cell DNA replication. Crit. Rev. Eukaryotic Gene Expr., 7: 125-157, 1997.